Skip to content
Disclosery

EXANE DERIVATIVES: SONY position timeline

Available 13F reports, 13D and 13G stakes and each Form 3, 4 and 5 line of EXANE DERIVATIVES on SONY, newest first. How the timeline and the estimate are built.

EXANE DERIVATIVES held 33 SONY shares at 2022-06-30 per its 13F-HR filed 2022-07-12.

the latest 13F is the newest step

  1. period ended2022-06-30
    13F 33 shares
    Change vs previous 13F -2,373 shares

    <0.01% of the 13F portfolio, value $2,698.

    13F-HR 0001623883-22-000006 filed by EXANE DERIVATIVES
    Filed (acceptance time not in the bulk data set), ingested

    Acceptance time not in the bulk data set (spec §4.2).

  2. period ended2022-03-31
    13F 2,406 shares
    Change vs previous 13F -258 shares

    0.07% of the 13F portfolio, value $247,125.

    13F-HR 0001623883-22-000004 filed by EXANE DERIVATIVES
    Filed (acceptance time not in the bulk data set), ingested

    Acceptance time not in the bulk data set (spec §4.2).

  3. period ended2021-12-31
    13F 2,664 shares
    Change vs previous 13F +26 shares

    0.08% of the 13F portfolio, value $336,751.

    13F-HR 0001623883-22-000002 filed by EXANE DERIVATIVES
    Filed (acceptance time not in the bulk data set), ingested

    Acceptance time not in the bulk data set (spec §4.2).

  4. period ended2021-09-30
    13F 2,638 shares
    Change vs previous 13F -40 shares

    0.07% of the 13F portfolio, value $291,724.

    13F-HR 0001623883-21-000008 filed by EXANE DERIVATIVES
    Filed (acceptance time not in the bulk data set), ingested

    Acceptance time not in the bulk data set (spec §4.2).

  5. period ended2021-06-30
    13F 2,678 shares
    Change vs previous 13F +1,800 shares

    0.07% of the 13F portfolio, value $279,269.

    13F-HR 0001623883-21-000006 filed by EXANE DERIVATIVES
    Filed (acceptance time not in the bulk data set), ingested

    Acceptance time not in the bulk data set (spec §4.2).

  6. period ended2021-03-31
    13F 878 shares
    Change vs previous 13F not available

    0.03% of the 13F portfolio, value $93,081.

    13F-HR 0001623883-21-000004 filed by EXANE DERIVATIVES
    Filed (acceptance time not in the bulk data set), ingested

    Acceptance time not in the bulk data set (spec §4.2).